Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of $18.71 billion. The enterprise value is $25.34 billion.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | Feb 21, 2025 |
Share Statistics
Royalty Pharma has 576.45 million shares outstanding. The number of shares has decreased by -1.46% in one year.
| Current Share Class | 433.32M |
| Shares Outstanding | 576.45M |
| Shares Change (YoY) | -1.46% |
| Shares Change (QoQ) | -0.63% |
| Owned by Insiders (%) | 12.66% |
| Owned by Institutions (%) | 75.66% |
| Float | 378.30M |
Valuation Ratios
The trailing PE ratio is 16.98 and the forward PE ratio is 6.95. Royalty Pharma's PEG ratio is 0.86.
| PE Ratio | 16.98 |
| Forward PE | 6.95 |
| PS Ratio | 6.43 |
| Forward PS | 5.31 |
| PB Ratio | 2.08 |
| P/TBV Ratio | 2.70 |
| P/FCF Ratio | 6.76 |
| P/OCF Ratio | 6.76 |
| PEG Ratio | 0.86 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 29.50 |
| EV / Sales | 11.19 |
| EV / EBITDA | n/a |
| EV / EBIT | 19.60 |
| EV / FCF | 9.15 |
Financial Position
The company has a current ratio of 1.44, with a Debt / Equity ratio of 0.74.
| Current Ratio | 1.44 |
| Quick Ratio | 1.43 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.75 |
| Interest Coverage | 5.73 |
Financial Efficiency
Return on equity (ROE) is 13.03% and return on invested capital (ROIC) is 4.73%.
| Return on Equity (ROE) | 13.03% |
| Return on Assets (ROA) | 4.67% |
| Return on Invested Capital (ROIC) | 4.73% |
| Return on Capital Employed (ROCE) | 7.62% |
| Revenue Per Employee | $22.86M |
| Profits Per Employee | $8.68M |
| Employee Count | 99 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.88% in the last 52 weeks. The beta is 0.47, so Royalty Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | +6.88% |
| 50-Day Moving Average | 30.90 |
| 200-Day Moving Average | 28.06 |
| Relative Strength Index (RSI) | 50.04 |
| Average Volume (20 Days) | 5,001,049 |
Short Selling Information
The latest short interest is 15.30 million, so 2.65% of the outstanding shares have been sold short.
| Short Interest | 15.30M |
| Short Previous Month | 16.13M |
| Short % of Shares Out | 2.65% |
| Short % of Float | 4.05% |
| Short Ratio (days to cover) | 3.53 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of $2.26 billion and earned $858.98 million in profits. Earnings per share was $1.91.
| Revenue | 2.26B |
| Gross Profit | 1.53B |
| Operating Income | 1.29B |
| Pretax Income | 673.24M |
| Net Income | 858.98M |
| EBITDA | n/a |
| EBIT | 1.29B |
| Earnings Per Share (EPS) | $1.91 |
Full Income StatementBalance Sheet
The company has $987.23 million in cash and $7.61 billion in debt, giving a net cash position of -$6.63 billion or -$11.49 per share.
| Cash & Cash Equivalents | 987.23M |
| Total Debt | 7.61B |
| Net Cash | -6.63B |
| Net Cash Per Share | -$11.49 |
| Equity (Book Value) | 10.34B |
| Book Value Per Share | 15.58 |
| Working Capital | 548.52M |
Full Balance SheetCash Flow
| Operating Cash Flow | 2.77B |
| Capital Expenditures | n/a |
| Free Cash Flow | 2.77B |
| FCF Per Share | $4.80 |
Full Cash Flow StatementMargins
Gross margin is 67.64%, with operating and profit margins of 57.10% and 37.95%.
| Gross Margin | 67.64% |
| Operating Margin | 57.10% |
| Pretax Margin | 58.79% |
| Profit Margin | 37.95% |
| EBITDA Margin | n/a |
| EBIT Margin | 57.10% |
| FCF Margin | 122.33% |
Dividends & Yields
This stock pays an annual dividend of $0.88, which amounts to a dividend yield of 2.71%.
| Dividend Per Share | $0.88 |
| Dividend Yield | 2.71% |
| Dividend Growth (YoY) | 4.94% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 46.03% |
| Buyback Yield | 1.46% |
| Shareholder Yield | 4.17% |
| Earnings Yield | 4.59% |
| FCF Yield | 14.80% |
Dividend DetailsAnalyst Forecast
The average price target for Royalty Pharma is $41.60, which is 28.16% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $41.60 |
| Price Target Difference | 28.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 6.61% |
| EPS Growth Forecast (5Y) | 34.69% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Royalty Pharma has an Altman Z-Score of 1.56 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.56 |
| Piotroski F-Score | 4 |